LAW OFFICE OF BRODSKY & SMITH, LLC ANNOUNCES CLASS ACTION AGAINST KARYOPHARM THERAPEUTICS, INC. (Nasdaq: KPTI)

BALA CYNWYD, July 25, 2019 /Access Wire/ – Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against Karyopharm Therapeutics, Inc. (“Karyopharm” or “the Company”) (Nasdaq – KPTI-News) for possible breaches of Federal Securities law.

According to the complaint, defendants made materially false and/or misleading statements and/or failed to disclose that: Throughout the Class Period, the Company continued to tout the commercial prospects for selinexor and consistently described selinexor as having a “predictable and manageable tolerability profile” and a “very nice safety profile,” and assured investors that it was “well tolerated” by patients. Karyopharm also claimed that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.

If you purchased shares of Karyopharm stock between March 2, 2017 and February 22, 2019

and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. The deadline for filing is September 23, 2019. You may contact Marc Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA  19004, or by calling toll free 877-LEGAL-90.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.